Type IMOZ/CBP (MYST3/CREBBP)is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation-Reference-Cited by-同舟云学术

Type IMOZ/CBP (MYST3/CREBBP)is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation

Published:2004-03-26 Issue:2 Volume:40 Page:140-145
ISSN:1045-2257
Container-title:Genes, Chromosomes and Cancer
language:en
Short-container-title:Genes Chromosom. Cancer

Author:

Rozman María,Camós Mireia,Colomer Dolors,Villamor Neus,Esteve Jordi,Costa Dolors,Carrió Ana,Aymerich Marta,Aguilar Josep Lluis,Domingo Alícia,Solé Francesc,Gomis Federico,Florensa Lourdes,Montserrat Emili,Campo Elias

Funder

Instituto de Salud Carlos III-FIS

Generalitat de Catalunya

Publisher

Wiley

Subject

Cancer Research,Genetics

Reference20 articles.

1. Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement;Aguiar;Blood,1997

2. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22);Baer;Blood,1997

3. Translocation (8;16) in a patient with acute myelomonocytic leukemia, occurring after treatment with fludarabine for a low-grade non-Hodgkin's lymphoma;Bernasconi;Haematologica,2000

4. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein;Borrow;Nat Genet,1996

5. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia;Carapeti;Blood,1998

Cited by 68 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic alterations in AML: Deregulated functions leading to new therapeutic options;International Review of Cell and Molecular Biology;2024

2. Alzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets;Molecular Neurobiology;2023-09-12

3. Pantothenate and L-Carnitine Supplementation Improves Pathological Alterations in Cellular Models of KAT6A Syndrome;Genes;2022-12-06

4. Monitoring KAT6A-CREBBP measurable residual disease in t(8;16) therapy-related acute myeloid leukemia;Leukemia Research;2022-05

5. Next generation epigenetic modulators to target myeloid neoplasms;Current Opinion in Hematology;2021-07-15